Sitting down with… Matthew Todd, Chair of Drug Discovery at UCL and founder of the Open Source Pharma movement.

What challenges do manufacturers face in developing ADCs?

Fines, approvals and anniversaries...What’s new in business?

Explore TOSOH’s expertise across all stages of therapeutic antibody development.

John Rossi, Director of Translational Sciences at Kite Pharma, talks about bright future of CAR T cell therapy.

Dick Sundh, Head of Europe at Kite, explains what it takes to commercialize CAR T cell therapy.

Ravi Nalliah explains his journey from biochemistry and molecular biology student, to chartered accountant, to supply chain CDMO founder.

Here we explore the challenges involved in ensuring CAR T cell therapies are delivered to patients safely and as quickly as possible.

How is pharma using advances in technology to its benefit?

A cell-free biologic could act as platform therapeutic for a variety of serious diseases.